Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
Identifieur interne : 000561 ( PubMed/Curation ); précédent : 000560; suivant : 000562Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
Auteurs : Daniel Batlle [États-Unis] ; Jan Wysocki [États-Unis] ; Karla Satchell [États-Unis]Source :
- Clinical science (London, England : 1979) [ 1470-8736 ] ; 2020.
Descripteurs français
- KwdFr :
- Animaux, Attachement viral, Haplorhini, Humains, Infections à coronavirus (traitement médicamenteux), Lignée cellulaire, Peptidyl-Dipeptidase A (physiologie), Pneumopathie virale (traitement médicamenteux), Protéines recombinantes (usage thérapeutique), Réplication virale, Solubilité, Virus du SRAS (pathogénicité).
- MESH :
- pathogénicité : Virus du SRAS.
- physiologie : Peptidyl-Dipeptidase A.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Protéines recombinantes.
- Animaux, Attachement viral, Haplorhini, Humains, Lignée cellulaire, Réplication virale, Solubilité.
English descriptors
- KwdEn :
- MESH :
- chemical , physiology : Peptidyl-Dipeptidase A.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- pathogenicity : Betacoronavirus, SARS Virus.
- chemical , therapeutic use : Recombinant Proteins.
- Animals, Cell Line, Haplorhini, Humans, Solubility, Virus Attachment, Virus Replication.
Abstract
A new coronavirus, referred to as SARS-CoV-2, is responsible for the recent outbreak of severe respiratory disease. This outbreak first detected in Wuhan, China in December 2019, has spread to other regions of China and to 25 other countries as of January, 2020. It has been known since the 2003 SARS epidemic that the receptor critical for SARS-CoV entry into host cells is the angiotensin-converting enzyme 2 (ACE2). The S1 domain of the spike protein of SARS-CoV attaches the virus to its cellular receptor ACE2 on the host cells. We thought that it is timely to explain the connection between the SARS-CoV, SARS-CoV-2, ACE2 and the rationale for soluble ACE2 as a potential therapy.
DOI: 10.1042/CS20200163
PubMed: 32167153
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000561
Links to Exploration step
pubmed:32167153Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?</title>
<author><name sortKey="Batlle, Daniel" sort="Batlle, Daniel" uniqKey="Batlle D" first="Daniel" last="Batlle">Daniel Batlle</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine/ Division of Nephrology/Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine/ Division of Nephrology/Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wysocki, Jan" sort="Wysocki, Jan" uniqKey="Wysocki J" first="Jan" last="Wysocki">Jan Wysocki</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine/ Division of Nephrology/Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine/ Division of Nephrology/Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Satchell, Karla" sort="Satchell, Karla" uniqKey="Satchell K" first="Karla" last="Satchell">Karla Satchell</name>
<affiliation wicri:level="1"><nlm:affiliation>Department Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32167153</idno>
<idno type="pmid">32167153</idno>
<idno type="doi">10.1042/CS20200163</idno>
<idno type="wicri:Area/PubMed/Corpus">000561</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000561</idno>
<idno type="wicri:Area/PubMed/Curation">000561</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000561</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?</title>
<author><name sortKey="Batlle, Daniel" sort="Batlle, Daniel" uniqKey="Batlle D" first="Daniel" last="Batlle">Daniel Batlle</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine/ Division of Nephrology/Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine/ Division of Nephrology/Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wysocki, Jan" sort="Wysocki, Jan" uniqKey="Wysocki J" first="Jan" last="Wysocki">Jan Wysocki</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine/ Division of Nephrology/Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine/ Division of Nephrology/Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Satchell, Karla" sort="Satchell, Karla" uniqKey="Satchell K" first="Karla" last="Satchell">Karla Satchell</name>
<affiliation wicri:level="1"><nlm:affiliation>Department Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical science (London, England : 1979)</title>
<idno type="eISSN">1470-8736</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>Cell Line</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Haplorhini</term>
<term>Humans</term>
<term>Peptidyl-Dipeptidase A (physiology)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Recombinant Proteins (therapeutic use)</term>
<term>SARS Virus (pathogenicity)</term>
<term>Solubility</term>
<term>Virus Attachment</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Attachement viral</term>
<term>Haplorhini</term>
<term>Humains</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Lignée cellulaire</term>
<term>Peptidyl-Dipeptidase A (physiologie)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Protéines recombinantes (usage thérapeutique)</term>
<term>Réplication virale</term>
<term>Solubilité</term>
<term>Virus du SRAS (pathogénicité)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Peptidyl-Dipeptidase A</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Peptidyl-Dipeptidase A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Recombinant Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protéines recombinantes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line</term>
<term>Haplorhini</term>
<term>Humans</term>
<term>Solubility</term>
<term>Virus Attachment</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Attachement viral</term>
<term>Haplorhini</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Réplication virale</term>
<term>Solubilité</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A new coronavirus, referred to as SARS-CoV-2, is responsible for the recent outbreak of severe respiratory disease. This outbreak first detected in Wuhan, China in December 2019, has spread to other regions of China and to 25 other countries as of January, 2020. It has been known since the 2003 SARS epidemic that the receptor critical for SARS-CoV entry into host cells is the angiotensin-converting enzyme 2 (ACE2). The S1 domain of the spike protein of SARS-CoV attaches the virus to its cellular receptor ACE2 on the host cells. We thought that it is timely to explain the connection between the SARS-CoV, SARS-CoV-2, ACE2 and the rationale for soluble ACE2 as a potential therapy.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32167153</PMID>
<DateCompleted><Year>2020</Year>
<Month>03</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1470-8736</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>134</Volume>
<Issue>5</Issue>
<PubDate><Year>2020</Year>
<Month>03</Month>
<Day>13</Day>
</PubDate>
</JournalIssue>
<Title>Clinical science (London, England : 1979)</Title>
<ISOAbbreviation>Clin. Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?</ArticleTitle>
<Pagination><MedlinePgn>543-545</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1042/CS20200163</ELocationID>
<Abstract><AbstractText>A new coronavirus, referred to as SARS-CoV-2, is responsible for the recent outbreak of severe respiratory disease. This outbreak first detected in Wuhan, China in December 2019, has spread to other regions of China and to 25 other countries as of January, 2020. It has been known since the 2003 SARS epidemic that the receptor critical for SARS-CoV entry into host cells is the angiotensin-converting enzyme 2 (ACE2). The S1 domain of the spike protein of SARS-CoV attaches the virus to its cellular receptor ACE2 on the host cells. We thought that it is timely to explain the connection between the SARS-CoV, SARS-CoV-2, ACE2 and the rationale for soluble ACE2 as a potential therapy.</AbstractText>
<CopyrightInformation>© 2020 The Author(s).</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Batlle</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Medicine/ Division of Nephrology/Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wysocki</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Medicine/ Division of Nephrology/Hypertension, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Satchell</LastName>
<ForeName>Karla</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Center for Structural Genomics of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R01 DK104785</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Clin Sci (Lond)</MedlineTA>
<NlmUniqueID>7905731</NlmUniqueID>
<ISSNLinking>0143-5221</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber>
<NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.-</RegistryNumber>
<NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000882" MajorTopicYN="N">Haplorhini</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007703" MajorTopicYN="Y">Peptidyl-Dipeptidase A</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053585" MajorTopicYN="Y">Virus Attachment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">2019 Novel Coronavirus</Keyword>
<Keyword MajorTopicYN="Y">Coronavirus</Keyword>
<Keyword MajorTopicYN="Y">angiotensin converting enzyme 2</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>02</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>03</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>03</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>3</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32167153</ArticleId>
<ArticleId IdType="pii">222345</ArticleId>
<ArticleId IdType="doi">10.1042/CS20200163</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000561 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000561 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= CovidV2 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:32167153 |texte= Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32167153" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a CovidV2
This area was generated with Dilib version V0.6.33. |